新辅助化疗对乳腺癌组织因子、基质金属蛋白酶-9和蛋白酶激活受体-2的表达及疗效的影响  

The impact of neoadjuvant chemotherapy on the expression of tissue factor,protease activated receptor-2 and matrix metalloproteinase-9

作　　者：赵建新[1] 林增茂[1] 段学宁[1] 刘荫华[1] 

机构地区：[1]北京大学第一医院乳腺疾病中心,北京100034

出　　处：《中国癌症杂志》2013年第3期195-199,共5页China Oncology

摘　　要：背景与目的:组织因子(tissue factor,TF)、基质金属蛋白酶-9(matrixmetalloproteinase-9,MMP-9)是影响乳腺癌转移和预后的重要因子,蛋白酶激活受体-2(proteinaseactivated receptor-2,PAR-2)是二者之间的介导因子。本研究旨在探讨乳腺癌组织中TF、PAR-2和MMP-9表达的变化与乳腺癌新辅助化疗疗效的关系。方法:应用二步法免疫组织化学方法检测85例乳腺癌新辅助化疗前后乳腺癌组织中TF、PAR-2和MMP-9的表达,分析新辅助化疗前后其表达的变化与新辅助化疗疗效的关系。结果:85例乳腺癌新辅助化疗患者病理完全缓解率(G5)为8.3%,其他患者在新辅助化疗后TF、PAR-2和MMP-9阳性率均降低,其中MMP-9显著降低(P<0.05)。新辅助化疗后,MMP-9表达阳性减弱的患者病理疗效显著好于阳性增强者(P<0.05);TF、MMP-9由阳性转为阴性患者的病理疗效显著好于由阴性转为阳性患者(P<0.05)。PAR-2的改变则与病理疗效无显著关系。结论:乳腺癌新辅助化疗后TF、MMP-9的阳性表达降低与病理缓解率相关,有助于判断新辅助化疗疗效。Background and purpose： TF and MMP-9 are important factors for prognosis and metastasis of breast cancer, PAR-2 is the mediate factor of them, this study aimed to evaluate the change of expressions of TF PAR-2 and MMP-9 in breast cancer patients after neoadjuvant chemotherapy and their correlations with pathologic response. Methods： The expressions of TF, PAR-2 and MMP-9 in 85 breast cancer tissues were examined by immunohistochemical technique （SP） before and after neoadjuvant chemotherapy. Correlation analysis were made between the change of expressions and pathologic response. Results： The strictly pathologic completely response rate （G5） was 8.3% in 85 breast cancer patients after neoadjuvant chemotherapy. The decrease of expression of MMP- 9 after neoadjuvant chemotherapy was statistically significant correlations with pathological response （P〈0.05）. The expression changes of TF and MMP-9 from positive to negative was statistically significant correlated with tumor pathological response（P〈0.05）. The expression change of PAR-2 showed rarely significant （P〉0.05）. Conclusion： The decrease of expression of TF and MMP-9 after neoadjuvant chemotherapy have statistically significant correlations with pathological response, would be probably useful for estimating the effect of neoadjuvant chemotherapy.

关 键 词：乳腺癌 组织因子 蛋白酶激活受体-2 基质金属蛋白酶-9 新辅助化疗 

分 类 号：R737.9[医药卫生—肿瘤]